Nuvalent Inc
NUVL
Jodie situation report
Nuvalent Inc's move is spreading beyond its market group.
No new filing conclusion is available. 8 of 13 group members are active now; 2 filing-linked outsiders are moving with the group, and 0 of 2 directly disclosed connections are confirming.
- At least 9 of 13 members remain active in the next snapshot.
- Capital-flow agreement rises above 55%.
- BMRN remains aligned with the group in the next market snapshot.
Invalidation: The live read weakens if participation falls to 4 of 13 members or fewer.
Who this business touches
The relationships behind NUVL
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depended on by
NUVBNuvation Bio Inc.competitorMar 2, 2026 ▾
“Other ROS1 inhibitors currently in clinical-stage development include Nuvalent’s zidesamtinib.”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 5 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
NUVL is currently a Participant in the organic co-movement group Biotechnology Therapeutics. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 1 filing-linked name are in the relationship map; none is currently confirmed as moving with the group.